Table 2.
Urinary AGT and renin levels and related factors according to the degree of proteinuria decrement at 24 weeks of valsartan treatment
| Non-decrementa (n = 152) |
Decrementb (n = 53) |
P | |
|---|---|---|---|
| Valsartan dose at 24 weeks | 0.668 | ||
| 320 mg | 96 (63.2%) | 31 (58.5%) | |
| 160 mg | 48 (31.6%) | 18 (34.0%) | |
| 80 mg | 8 (5.3%) | 4 (7.5%) | |
| Baseline uPCR | 1.64 (1.22–2.49) | 2.66 (1.84–3.95) | < 0.001 |
| Baseline MAP | 111.4 ± 12.0 | 112.1 ± 12.3 | 0.713 |
| Baseline ln(uAGT/Cr) (μg/g) | 3.29 (2.53–4.21) | 3.92 (3.39–4.59) | 0.004 |
| Baseline ln(uR/Cr) (pg/g) | −1.25 (−2.11–0.47) | −0.35 (− 1.96–1.73) | 0.047 |
| Δln(uAGT/Cr) (μg/g)c | 0.00 (−0.79–0.63) | − 0.76 (−2.07–0.80) | < 0.001 |
Abbreviations: MAP mean arterial pressure, uAGT/Cr urinary angiotensinogen/creatinine ratio, uPCR urinary protein/creatinine ratio, uR/Cr urinary renin/creatinine ratio
aNon-decrement: patients with uPCR decrement < 1 mg/mg
bDecrement: patients with uPCR decrement ≥1 mg/mg
cΔln(uAGT/Cr) = [ln(uAGT/Cr) at 24 weeks] - [baseline ln(uAGT/Cr)]